Anthropic partners with six drug developers, targets rare childhood diseases with Claude
JHochderffer · x · 2026-10-28
Anthropic is working with six drug developers and launching its own programs targeting rare childhood muscular dystrophies, with Claude handling much of the scientific and operational work.
Claude is reportedly helping improve experimental treatments and cut drug development paperwork. The replying poster argues AI-driven drug development is a more profitable path than selling tokens, adding that the future of inference is local and on-device — a personal take.
More from AGI Musings
- Economist Bharat Chandar named Research Director for AI Economics at DigEconLab — soumitrashukla9 · 2026-10-28
- New research agenda on 'inter-AI morality': how AI systems perceive and treat each other — dioscuri · 2026-10-28
- Essay: AI dissolves intellectual communities, making private intellectual work rarer — zetalyrae · 2026-10-28
- LeCun: 'No way in hell' LLMs reach human-level AI, calling 'country of geniuses in a data center' BS — examachine · 2026-10-28
- Quine on why modal contexts break substitutivity in equational reasoning — zetalyrae · 2026-10-28
- PackyM's old sci-fi tech exploration now reads like an AI-era runbook — generativist · 2026-10-28